Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ATARI: ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

NCT04065269 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT04065269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04065269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ATARI: ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 27, 2019
Completion date
August 31, 2026
Enrollment
174 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

gynaecological cancers